Clincial Value of 18F-FDG PET/CT in Amyloid Light Chain Amyloidosis: Whether It’s Useful or Not?
Yongming Zhao,Qian Wang
2018-01-01
Abstract:1427 Background: Amyloid light chain (AL) amyloidosis is a disease caused by the deposit of insoluble polymeric protein fibrils formed from misfolding of monoclonal immunoglobulin light chain that ultimately lead to regional or systematic disruption of tissues and organs. It is mainly associated with abnormal proliferation of clonal plasma cells, and a few with lymphocyte proliferation. Although some previous case reports described the 18F-FDG PET / CT imaging characteristics of amyloidosis involving a certain tissue or organ, a series of studies still be rare. Objectives: To analyze the clinical and 18F-FDG PET / CT imaging data of patients with AL amyloidosis and explore the value of 18F-FDG PET / CT in AL amyloidosis. MATERIALS AND METHODS: From May 2016 to November 2017, 21 consecutive patients with clinically confirmed or suspected AL amyloidosis and 18F-FDG PET/CT imaging were retrospectively analyzed, including 15 males and 6 females with an average age of 62.0 ± 10.0 years old (rang from 40-84 years old). 18F-FDG PET/CT scans were taken in the recommended standard condition with a dedicated PET/CT scanner (Discovery VCT, GE, American). Three experienced nuclear medical physicians read the images, and diagnosis was made by consensus. Positive PET/CT was defined as presence of morphological change in CT part and/or focal increased FDG uptakes in PET part which is higher than the background and can be excluded from physiological uptake. The final diagnoses and involved tissue or organ was established according to patient’s clinical, imaging and pathological examinations. Compared with the final diagnoses, we analyzed the detection rate of 18F-FDG PET/CT to detect the associated malignancy and involved tissues or organs in AL amyloidosis. Results: Of all 21 cases, 19 were diagnosed as systemic AL amyloidosis and 3 localized AL amyloidosis. 23.8% (5/21) had malignancy, including 3 cases of systemic AL amyloidosis complicated with multiple myeloma, 1 case of localized AL amyloidosis with lymphoma and 1 case of localized amyloidosis with colon cancer. According to the final diagnosis, a total of 50 involved tissues or organs were established, with kidney (24%, 12/50) involvement is most common, followed by heart (18%, 9/50), soft tissue (18%, 9/50), lung (10%, 5/50), lymph node (10%, 5/50), peripheral nerve (8%, 4/50), gastrointestinal tract (6%, 3/50), ureter (2%,1/50), bladder (2%, 1/50) and liver (2%, 1/50). In all this group, the overall positive rate of PET/CT was 61.9% (13/21). In 5 cases with malignancy, the positive rate was 80% (4/5), of which 2 cases manifested both malignant tumor and amyloid-related organ involvement, 1 only malignant tumor and 1 only amyloid-related organ involvement. Among 16 cases without malignancy, the positive rate was 56.3% (9/16), all of which indicated the involvement of amyloidosis. Of the 50 clinically confirmed amyloid-related tissues or organs, 18 were identified by PET/CT, with an overall detection rate of 38%. When lymph node, lung, soft tissue and heart were involved, the detection rate of PET/CT was 100% (5/5), 80% (4/5), 66.7% (6/9), and 44.4% (4/9), respectively. When the urinary and digestive systems were involved, PET / CT imaging showed no positive. Conclusions: 18F-FDG PET/CT is useful in AL amyloidosis. It can help find the associated malignancy and detect 1/3 amyloid-related tissues or organs. In organs with no physiological distribution of 18F-FDG, the detection rate is especially high.